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nasopharyngeal carcinoma (NPC) stage cT3N2 Mx. Pretreat-
ment [18F]-fluorodeoxyglucose (FDG) positron emission
tomography (PET) scan showed intense FDG uptake in the
nasopharynx (SUV Z 13.0), right retropharyngeal node
(standardized uptake value (SUV) Z 8.4), left retro-
pharyngeal node (SUV Z 10.5), left carotid space node
(SUV Z 5.5), and multiple FDG-avid lesions in the periph-
eral lung of the right upper lobe (SUVZ 10.1 for the largest
lesion). Wedge resection of the lung lesions was performed
and revealed as cryptococus. The patient received
concurrent chemoradiotherapy (CCRT), 70 Gy/35 fractions/
7 weeks plus 2 cycles cisplatin-based chemotherapy.
Complete response was obtained by conventional staging
workups. The plasma EpsteineBarr virus (EBV) DNA
concentration was 2612 copies/mL before treatment and
dropped to an undetectable level 1 week after CCRT.
Unfortunately, plasma EBV DNA rose from undetectable to
411 (4 months after CCRT), and later to 1341 copies/mL
(5 months after CCRT). A second PET scan showed complete
resolution of previous NPC, metastatic regional lymph
nodes, and right upper lung but new FDG-avid lesions in T12
spine (SUV Z 4.1) and right paravertebral region of the T9* Corresponding author. Department of Radiation Oncology,
Taichung Veterans General Hospital, Taiwan, Number 160, Section
3, Taichung-Kang Road, Taichung City 407, Taiwan.
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doi:10.1016/j.jfma.2011.05.006spine (SUV Z 4.5). The patient was symptom-free at this
time; however, CT-guided biopsy revealed the right para-
vertebral lesion to be metastatic NPC. He received salvage
chemotherapy, and a complete response was documented
by a third PET scan. Local irradiation (24 Gy/3 fractions)
boost followed by oral tegafur-uracil 200 mg twice daily
plus cyclophosphamide 50 mg once daily were adminis-
tered. The plasma EBV DNA rose from 1341 copies/mL
before CT-guided biopsy up to 8105 copies/mL when we
started salvage chemotherapy but rapidly dropped to an
undetectable level after chemotherapy. The plasma EBV
DNA remained at an undetectable or very low level
(<100 copies/mL) without any symptoms for 6 months but
rose to 2597 copies/mL. A fourth PET scan revealed
multiple mediastinal lymph nodes metastasis (SUV Z 8.9).
So, oral chemotherapy was shifted to intravenous chemo-
therapy, and a partial response of the mediastinal nodes
was obtained. Local boost radiotherapy of 20 Gy/2 fractions
to the metastatic nodes was administered and oral
chemotherapy resumed. Complete remission was observed
by conventional workups and a PET scan. Fig. 1 demon-
strates the serial changes of the plasma EBV DNA in relation
with disease status and treatment delivery.
Although functional imaging by 18F-FDG PET scan or
PET/CT scan1e3 was reported as an encouraging diagnostic
modality in NPC, accurate interpretation of the hyper-
metabolic lesions in PET scan is a somewhat difficult issue
because false positives and false negatives are not& Formosan Medical Association. All rights reserved.
Figure 1 The serial changes of the plasma EBV DNA in rela-
tion with disease status, treatment delivery and response.
EBV DNA assay and PET in NPC 119uncommon. In addition, repeat PET scans for all patients
will result in a high financial burden. In contrast, circulating
EBV DNA is a less expensive test that has been demon-
strated to be a reliable, specific biomarker in NPC.4,5 The
current case demonstrated that monitoring plasma EBV DNA
could accurately reflect disease status, not only for earlydetection of distant metastasis but also for treatment
response evaluation, resulting in long-term disease-free
survival for a patient who had a pathologically verified
distant metastasis.
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